Profit from sales of medicines is incentivizing pharma companies to further invest in research and innovation, which is undoubtedly in the public interest. Profit is evidently linked to prices. Prices of patented medicines are exponentially rising around the world. As a result, there is an increase in public expenditure and the diminution of access to medicines across all income groups of countries. Hence there is a conflict between two public interests: innovation on one hand and affordability on the other.
Continue reading Patented medicines: how to determine and curb prices?